Skip to content
value.today

Hexagon Bio Inc.

🇺🇸 Menlo Park, California, USABiotechnologyFounded 2016
Total raised
$149 M
4 rounds on record
Latest round
$67 M
Sep 2022
First round on record
Jun 2017
Today
Private
No later event on record

Funding rounds

4 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Hexagon Bio Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Sep 2022$67 MNo. 4$50 to $250 million

Hexagon Bio Inc.: Raise no. 4, Sep 2022

Investors in this round

20 investors had bought by the notice of Oct 11, 2022: 20 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$67 M of $80 M offered; $13 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Brian T Naughton · Executive Officer, Director
  • Maureen E Hillenmeyer · Executive Officer, Director
  • Alex T Kolicich · Director
  • David T Goeddel · Director
  • Jakob T Loven · Director
  • Juan T Jaen · Director
  • Mridula T Ray · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Maureen Hillenmeyer, Chief Executive Officer. Source: SEC Form D, newest notice filed Oct 11, 2022. Read the notice at the SEC.

equitySEC
Jun 2021$61 MNo. 3$50 to $250 million

Hexagon Bio Inc.: Raise no. 3, Jun 2021

Investors in this round

14 investors had bought by the notice of Jul 19, 2021: 14 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$61 M (amount offered: indefinite)
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Brian Naughton · Executive Officer, Director
  • Maureen Hillenmeyer · Executive Officer, Director
  • Alex Kolicich · Director
  • David Goeddel · Director
  • Jakob Loven · Director
  • Juan Jaen · Director
  • Mridula Ray · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Maureen Hillenmeyer, Chief Executive Officer. Source: SEC Form D, newest notice filed Jul 19, 2021. Read the notice at the SEC.

equitySEC
Apr 2018$12 MNo. 2$10 to $50 million

Hexagon Bio Inc.: Raise no. 2, Apr 2018

Investors in this round

12 investors had bought by the notice of Jul 31, 2018: 12 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$12 M of $12 M offered
Smallest investment taken
no minimum stated
What was sold
debt, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Brian T. Naughton · Executive Officer, Director
  • Colin James Bell Harvey · Executive Officer, Director
  • Maureen E. Hillenmeyer · Executive Officer, Director
  • Alex Bell Kolicich · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Alan C. Mendelson, Secretary. Source: SEC Form D, newest notice filed Jul 31, 2018. Read the notice at the SEC.

debt, optionsSEC
Jun 2017$8 MNo. 1$2 to $10 million

Hexagon Bio Inc.: Raise no. 1, Jun 2017

Investors in this round

9 investors had bought by the notice of Jul 20, 2017: 9 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$8 M of $8 M offered; $0 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Maureen E. Hillenmeyer · Executive Officer, Director
  • Alex Bell Kolich · Director
  • Brian T. Naughton · Director
  • Colin James Bell Harvey · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Alan C. Mendelson, Secretary. Source: SEC Form D, newest notice filed Jul 20, 2017. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Hexagon Bio Inc. chose not to state its revenue in its newest notice of a funding round (Oct 2022).

    SEC Form D · Oct 2022

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Oct 2022

That is all the official record says: Hexagon Bio Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of Hexagon Bio Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 4 rounds above had up to 20 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Hexagon Bio Inc.
NameRoleNamed in
Brian T NaughtonExecutive officerOct 2022
Maureen E HillenmeyerExecutive officerOct 2022
Brian NaughtonExecutive officerJul 2021
Maureen HillenmeyerExecutive officerJul 2021
Brian T. NaughtonExecutive officerJul 2018
Colin James Bell HarveyExecutive officerJul 2018
Maureen E. HillenmeyerExecutive officerJul 2018
Alex T KolicichDirectorOct 2022
Brian T NaughtonDirectorOct 2022
David T GoeddelDirectorOct 2022
Jakob T LovenDirectorOct 2022
Juan T JaenDirectorOct 2022
Maureen E HillenmeyerDirectorOct 2022
Mridula T RayDirectorOct 2022
Alex KolicichDirectorJul 2021
Brian NaughtonDirectorJul 2021
David GoeddelDirectorJul 2021
Jakob LovenDirectorJul 2021
Juan JaenDirectorJul 2021
Maureen HillenmeyerDirectorJul 2021
Mridula RayDirectorJul 2021
Alex Bell KolicichDirectorJul 2018
Brian T. NaughtonDirectorJul 2018
Colin James Bell HarveyDirectorJul 2018
Maureen E. HillenmeyerDirectorJul 2018
Alex Bell KolichDirectorJul 2017